Gene expression profiling of pediatric acute promyelocytic leukemia

Acute promyelocytic leukemia (APL) is categorized as the M3 subtype in the French-American-British classification system. It represents a unique subtype of acute myeloid leukemia (AML) characterized by the t(15;17)/PML::RARA fusion, with leukemic cells arrested at the promyelocytic stage of myelopoiesis. Pediatric APL accounts for approximately 5%-10% of all AML. While the prognosis of APL patients has dramatically improved with the use of all-trans retinoic acid (ATRA) and arsenic trioxide, relapse patients still exist. To reveal the molecular biological basis of pediatric APL, we performed an integrative analysis of the trasncriptome and methylome.